WPD Pharmaceuticals Sp. z o.o.

WPD Pharmaceuticals is a Polish biotech company developing innovative oncology therapies for high-mortality cancers. While initially focused on lethal brain tumors like glioblastoma, WPD has built a diverse pipeline of patented drug candidates (licensed from Wake Forest University) including cutting-edge antibody-drug conjugates. Our flagship ADC, WPD401, co-developed with Wake Forest, uniquely targets four tumor-specific receptors (IL-13Rα2, EphA2, EphA3, EphB2) found in some of the toughest-to-treat cancers. Originally designed for glioblastoma, WPD401 has shown potent activity in other aggressive tumors that overexpress these receptors – for example, triple-negative breast, pancreatic, and certain lung cancers – thereby broadening its clinical potential into multiple high-need indications. Backed by this innovative multi-target approach and encouraging preclinical results, WPD is now advancing toward clinical trials in the United States. We are actively seeking strategic partners to co-develop and unlock the full potential of our pipeline, with the aim of delivering life-changing therapies for patients with limited treatment options. The controlling shareholder of WPD Poland is ACRX Investments Limited.